AffaMed gets commercialisation rights for Lilly’s Galcanezumab in Mainland China
Galcanezumab is a monoclonal antibody, which was approved by the US Food and Drug Administration in 2018 for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Jan 23
Galcanezumab is a monoclonal antibody, which was approved by the US Food and Drug Administration in 2018 for…
18 Jan 23
The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Jan 23
Tezspire is a human monoclonal antibody that inhibits the action of TSLP, an important epithelial cytokine responsible for…
13 Jan 23
The EC approval expands Xofluza’s indication in the EU to include the treatment of uncomplicated influenza and for…
13 Jan 23
The new model is intended for the design of new therapeutic targets for untreatable diseases and is expected…
12 Jan 23
Airsupra is a pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol and budesonide, being jointly developed…
11 Jan 23
The acquisition builds on a multi-year strategic collaboration between BioNTech and InstaDeep and is expected to add around…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 23
Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jan 23
The acquisition will provide AstraZeneca with access to global rights to baxdrostat, CinCor’s novel aldosterone synthase inhibitor drug…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Jan 23
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody, indicated as a 100mg/mL intravenous injection, for the…